Suraksha Diagnostic IPO
Historical offer record. This offer is closed for applications. Prices and subscriptions describe the past offer; GMP observations are unofficial past records, not current quotes or listing predictions.
Data provider: FinAPI. This is a third-party summary, not an official prospectus. Read our data limitations and editorial policy.
No GMP observations are available for this historical offer record. No premium or listing-gain estimate is shown.
Price band
₹420 – ₹441
Lot size
34 shares
Offer application amount
₹14,994
Issue size
₹846.25 Cr
Historical offer amount for 1 lot at the upper issue price. Confirm the lot size and application terms in the issuer prospectus.
Reported IPO schedule
| Open date | 29 Nov 2024 |
| Close date | 3 Dec 2024 |
| Allotment finalisation | 4 Dec 2024 |
| Refund initiation | 5 Dec 2024 |
| Shares credited to demat | 5 Dec 2024 |
| Reported listing date | 6 Dec 2024 |
About Suraksha Diagnostic
Suraksha Diagnostic was incorporated on 15 March 2005 and offers services like Medical testing, diagnostic solutions, and medical consultation. It is headquartered in East India and caters end-to-end solutions of pathology and radiology testing to its consumers through its functional network. Over time, it has collected various awards for identifying the brand’s awareness and focus in business. It has a good portfolio of over 2,300 tests including 788 pathology tests like basic biochemistry and haematology. 647 tests including advanced biochemistry, histopathology, and molecular pathology. In FY 2022 and 2024, the compounded annual growth rate(CAGR) of 20.87% in revenue and net income for FY 2024 was 23.13 crore. Furthermore, The leading diagnostic network with a strong presence in eastern India, outstanding profitability, and consistency in financial performance is a strength of this company. Due to its expertise have 1,522 permanent staff in the company.
Company summary supplied by FinAPI. Read the prospectus for the issuer's disclosures and audited financials.
Offer documents and primary references
Read the issuer's offer document and any corrigenda for the full disclosures. A third-party details page is a summary; SEBI filing access does not imply an endorsement of the offer or this website.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.